In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on 908 Devices (MASS – Research Report), with a price target of $17.00. The company’s shares closed yesterday at $6.96.
Arias covers the Healthcare sector, focusing on stocks such as Danaher, Illumina, and 10x Genomics. According to TipRanks, Arias has an average return of -6.2% and a 40.22% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 908 Devices with a $17.00 average price target.
See today’s best-performing stocks on TipRanks >>
Based on 908 Devices’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $14.3 million and a GAAP net loss of $7.09 million. In comparison, last year the company earned a revenue of $15.8 million and had a GAAP net loss of $6.26 million
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MASS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
908 Devices (MASS) Company Description:
908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics and adjacent markets.
Read More on MASS:
